DMPK-Targeting RNA Conjugate for DM1 Cellular Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNAi therapies for muscle dystrophy, such as myotonic dystrophy type 1 (DM1), face challenges with poor intracellular uptake, limited blood stability, and non-specific immune stimulation, hindering their effectiveness in modulating gene expression and treating muscle atrophy.
Innovation Solution
Development of a polynucleic acid molecule conjugate comprising an anti-transferrin receptor antibody or its antigen binding fragment conjugated to a polynucleic acid molecule that hybridizes to the DMPK gene, optimized with specific modifications and linkers to enhance intracellular uptake, stability, and reduce toxicity, thereby mediating effective RNA interference against DMPK.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNAi therapy is administered to treat muscle dystrophy, then gene expression modulation is achieved, but intracellular uptake is poor
Solution Approach 1:
The patent employs a transferrin receptor-targeting ligand as an intermediary carrier to mediate the delivery of RNAi molecules into cells. The ligand binds to transferrin receptors on the cell surface, facilitating endocytosis and intracellular delivery of the RNAi therapeutic, thereby resolving the poor uptake issue while maintaining gene silencing efficacy
Solution Approach 2:
The invention creates a composite structure consisting of a ligand (targeting transferrin receptor), a linker, and an RNAi molecule (siRNA or shRNA). This composite conjugate combines the targeting capability of the ligand with the gene-silencing function of RNAi, enabling both efficient cellular entry and therapeutic effect
2Reliability
If RNAi therapy is administered to treat muscle dystrophy, then gene expression modulation is achieved, but blood stability is limited
Solution Approach 1:
The patent modifies the chemical parameters of the RNAi molecule by conjugating it to a ligand and incorporating modified nucleotides (such as 2'-O-methyl modifications). These parameter changes enhance the molecule's resistance to nucleases in the bloodstream, thereby improving blood stability and circulation half-life while preserving its ability to induce gene silencing
3Reliability
If RNAi therapy is administered to treat muscle dystrophy, then gene expression modulation is achieved, but non-specific immune stimulation occurs
Solution Approach 1:
The patent applies local quality modifications by introducing specific chemical modifications at particular positions of the RNAi molecule (e.g., 2'-O-methyl modifications at specific nucleotides). These localized modifications reduce immune recognition and activation of innate immune pathways while maintaining the essential gene-silencing function of the RNAi molecule
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugate achieves significant reduction in DMPK mRNA expression, effectively modulating muscle atrophy and treating DM1 by enhancing intracellular delivery and stability while minimizing off-target effects.
Implementation Method 1
a polynucleic acid molecule that hybridizes to a target sequence of DMPK
Implementation Method 2
The polynucleic acid molecule conjugate mediates RNA interference against the DMPK
Implementation Method 3
an anti-transferrin receptor antibody or antigen binding fragment thereof conjugated to a polynucleic acid molecule
Data Source
AI summary
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).